BMI1 and breast carcinoma: For the route blocking transcription, broad spectrum histone deacetylase (HDAC) inhibitors have been shown to inhibit the expression of BMI1 and the activity of the PRC1 complex in breast cancer cells, as measured through a decrease of H1AK119ub1 [236,237].